R&D
R&D Performance
Heat‑resistant ABS/ASA with excellent processability and appearance quality
Development of differentiated automotive ABS/ASA through combined polymerization and compounding technologies
- Heat‑resistant ABS offering excellent paintability and processability via surface‑modification technology
- Automotive ASA enabling ultra‑deep black and high‑gloss components through proprietary polymers
High‑purity IPA for semiconductor applications
Ultra‑high‑purity cleaning solutions for semiconductor manufacturing
- Production system based on proprietary processes with excellent energy efficiency and selectivity
- -Ensuring stability and high quality through high‑efficiency hybrid (distillation/non‑distillation) purification technology
Modified SSBR for high‑performance tires
Cutting‑edge solutions enabling low rolling resistance and optimal wear and braking performance
- High‑efficiency modification technologies for differentiated performance in eco‑friendly EV tires
- Precise polymerization control ensuring optimal processability and overcoming performance trade‑offs
Ternary (+) electrode materials
Developed ternary (+) electrode materials for high-capacity and safe lithium-ion rechargeable batteries
- -Enhanced the capacity of lithium-ion rechargeable batteries and their performance at high temperatures by forming a stable structure of three elements: nickel, manganese, and cobalt
- -Minimized the volume change during charging and discharging to increase the lifespan of the battery and improve its safety
Highly Dispersible Bundle-Type CNT
Developed nanoscale carbon materials with optimal performance as conductive additives for secondary batteries
- Advanced the bundle type by dividing and adjusting the size of particles through support control technology
- Achieved excellent quality using fluidized bed reaction technology favorable for mass production
Zemiglo
Korea’s first new diabetes treatment drug
- Controls blood sugar levels by increasing the actions of incretin hormones that promote insulin secretion
- Fewer side effects such as low blood sugar and weight gain compared to other drugs
- Became the first new Korean drug to reach KRW 100 billion in sales in 2020
Eupolio
World’s first attenuated Sabin IPV to receive the prequalification status from the WHO
- Next-generation inactivated vaccine that has chemically removed pathogenicity using attenuated (weakened) viruses
- Enhanced stability compared to existing live vaccines
